 The FDA has recently approved Intacs®
for the treatment of keratoconus.
This is great news for some people facing a corneal
transplant.
The primary reason
a person makes the unenviable decision to undergo a corneal
transplant is to regain or retain vision, not because their
cornea is about to fall off. My objective was to uncover and
implement a method of reshaping the cornea to compensate for
the abnormalities of severe myopia and astigmatism created by
disease and in some cases exacerbated iatrogenically. The ICR
technology has provided a mechanism for reshaping and
reinforcing the weakened cornea which is additive and
forgiving.
My patients have experienced
improved quality of vision and quality of life. My
youngest keratoconus patient treated with Intacs is 8 years
old. In the Intacs eye the young boy is doing great; however,
in the other eye, he is experiencing a rejection from the
transplant. I firmly believe that Intacs is the best and
safest option for keratoconus sufferers.
The surgery is a simple
outpatient procedure with minimal discomfort - if any.
|
